Is Erdafitinib already on the market in China?

Erdafitinib (Erdafitinib) is an oral tyrosine kinase inhibitor, mainly targeted at patients with advanced or metastatic urothelial carcinoma (bladder cancer) with fibroblast growth factor receptor (FGFR) 1 to 4 mutations or amplifications. As a targeted therapy drug, erdafitinib can selectively inhibit the FGFR signaling pathway, thereby blocking the proliferation, migration and survival of cancer cells. Compared with traditional chemotherapy, erdafitinib shows significant efficacy and controllable safety in patients with specific genetic backgrounds, demonstrating the value of medicine in the management of urothelial cancer.

In China, erdafitinib has been officially launched and is provided in the form of erdafitinib tablets (Balco/Balversa). Common specifications include 5mg 28 tablets, 3mg 56 tablets and 4mg*28 tablets, allowing doctors to adjust the dosage according to the patient's body surface area, genetic mutation status and tolerance. However, due to the short time the drug has been on the market in China, the inventory of hospitals and pharmacies in some areas may be limited, and its price is not included in the national medical insurance, making it difficult for patients to purchase it directly. Therefore, some patients may choose to obtain original drugs through formal overseas channels to ensure continued treatment without interruption.

For clinicians, it is important to understand the marketing status and supply channels of erdafitinib. On the one hand, drugs can be obtained through formal domestic channels for patients with indicated indications. On the other hand, attention should also be paid to the source reliability and quality standards of drugs to ensure patient drug safety. In addition, before patients receive erdafitinib treatment, they usually need to undergo FGFR gene testing to confirm whether there are targetable mutations or amplifications to ensure the maximum efficacy and accuracy of the drug.

In summary, erdafitinib has been launched in China, providing a new targeted treatment option for patients with advanced urothelial cancer related to FGFR mutations. However, since it has not yet been included in medical insurance, access channels are relatively limited. Patients and doctors need to conduct a comprehensive assessment based on drug accessibility, economic burden, and treatment needs when formulating treatment plans.

Reference materials：https://www.balversa.com/